Weak dollar hits Bayer healthcare sales:
This article was originally published in Clinica
First-half sales of Bayer's healthcare division, which includes diagnostics, rose 2% on year-earlier levels to DM 5,600 million ($3,916 million). Turnover suffered badly from the weak dollar, the company comments. Group sales climbed 4.5% to DM 23,184 million. Products from the Diagnostics business group are among those due to be produced in Beijing by Bayer's new Chinese pharmaceutical joint venture. An agreement to set up the venture was signed in July with Beijing Economic Technological Investment Development Corporation (BETIDC), which holds a 5% stake.